Advisory Services Network’s BridgeBio Pharma BBIO Stock Holding History

Advisory Services Network’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10	Closed	-$743	–	2385
2026 Q1	$743	Buy	+10	New	+$725	﹤0.01%	4360
2025 Q4	–	Sell	-1	Closed	-$52	–	2029
2025 Q3	$52	Buy	+1	New	+$49	﹤0.01%	4461
2020 Q4	–	Sell	-60	Closed	-$2.9K	–	3303
2020 Q3	$2K	Buy	+60	New	+$1.89K	﹤0.01%	3065

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Advisory Services Network's BBIO Position: Q2 2026 in Review

Advisory Services Network sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 10 shares — an estimated $743 sold.

Advisory Services Network first reported a position in BBIO in Q3 2020 and held it in 3 quarters. The position peaked at $2K in Q3 2020. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Advisory Services Network reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 10 BridgeBio Pharma shares in Q2 2026, an estimated $743.
Advisory Services Network first reported a position in BridgeBio Pharma in Q3 2020 and held it in 3 quarters.
Advisory Services Network's BridgeBio Pharma position peaked at $2K in Q3 2020.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.